Dear All, Two stops on our tour today: (i) an excellent survey of incentive models and (ii) a final communique from the recent G7 meetings. First up, CGD (Center for Global Development) have released a report (link) entitled “Leveraging Purchasing Systems to Ensure Access, Stewardship, and Innovation: A Landscape Review of Current and Potential Market Structures
Dear All, On the heels of yesterday’s (i) patient-focused meeting at the Capitol yesterday where 5 Members of Congress spoke in person (video, press release) in support of passage of the PASTEUR Act and (ii) strong shout-out to PASTEUR by Congressman Mike Doyle during the Energy and Commerce Committee markup session, CARB-X today announced commitments of
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact
Dear All, On 6 Jan 2022, we had the announcement of the creation of in France of the ARPEGE consortium (AppRoche théraPeutique Economique & diaGnostique de l’antibiorésistancE) or “Economic, diagnostic and therapeutic approach to antibiotic resistance.” Somebody definitely had fun with that acronym! Here’s what you need to know: The French government is providing €9m of
https://www.youtube.com/watch?v=f0-xt3FrAGU&ab_channel=AMR.SolutionswithDr.JohnRex Dear All, VERY exciting news on the Pull incentive front: The G7 Finance Ministers have released a statement on Actions to Support Antibiotic Development, aiming to strengthen G7 preparedness against the “silent pandemic” of antimicrobial resistance. Implicitly, this is a statement that is agreed and endorsed by the political leadership of each country —
Dear All (and with thanks to ATMF’s Damiano de Felice for co-authoring this newsletter), Last week, the team at ATMF (Access to Medicine Foundation) released a 3rd update to the AMR Benchmark series that they started in 2018. For those not familiar with the ATMF, its independent analyses (all its funding is from governments or private
Dear All, Following release back in June of a preview (22 June 2021 newsletter), we now have the official introduction of Cures 2.0 by the bipartisan team of U.S. Reps. Diana DeGette (D-CO) and Fred Upton (R-MI)! Here are the links you need: Cures 2.0 legislation is available here. Section-by-section summary of the bill is available here. There
Dear All, The BEAM Alliance, along with its partners (CARB-X, the Novo REPAIR Impact Fund, the IMI AMR Accelerator, and the European Biotechnology Magazine) converted their annual AMR conference into a virtual event held 24-26 Aug 2021. As usual, it was excellent! I know we’re all really, REALLY tired of virtual meetings but the 2h/day x 3 day themed format worked well:
Dear All, A brief note today as I am traveling (yes, really … first time in almost 18 months) but wanted to share these 3 important upcoming meetings. The theme I expect to hear running through them all is that (i) innovation is possible (the CARB-X Year 5 report is amazing!), (ii) new antibiotics must both
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Post-newsletter addendum: A slide deck that summarizes the data from the paper is now available. We talked in a 22 Mar 2021 newsletter about ensuring access to new antibiotics and you should take a moment to refresh your memory of its discussions of